中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2013年
18期
2784-2786
,共3页
莫沙必利%胰激肽原酶%糖尿病%膀胱,神经源性%治疗结果%生活质量
莫沙必利%胰激肽原酶%糖尿病%膀胱,神經源性%治療結果%生活質量
막사필리%이격태원매%당뇨병%방광,신경원성%치료결과%생활질량
Mosapride%Pancreatic kininogenase%Diabetes mellitus%Urinary bladder,neurogenic%Treatment outcome%Quality of life
目的 探讨莫沙必利联合胰激肽原酶治疗糖尿病神经源性膀胱(DNB)的疗效及安全性.方法 将120例糖尿病神经源性膀胱患者采用数字表法随机分为对照组和观察组,各60例.两组患者均接受基础治疗,包括降糖、降压、营养神经以及调节血脂等,观察组在此基础上加用莫沙必利与胰激肽原酶治疗,两组治疗时间均为3周.观察两组疗效、血糖、血脂、尿动力学、生活质量以及不良反应发生率.结果 观察组总有效率为93.33％,明显高于对照组的65.00％(χ2=14.602,P＜0.0l)；观察组不良反应发生率为8.33％,明显低于对照组的20.00％(χ2=11.368,P＜0.01).结论 莫沙必利联合胰激肽原酶治疗糖尿病神经源性膀胱的疗效显著,能够明显改善患者的临床症状及提高患者的生活质量,应在临床上加以推广并应用.
目的 探討莫沙必利聯閤胰激肽原酶治療糖尿病神經源性膀胱(DNB)的療效及安全性.方法 將120例糖尿病神經源性膀胱患者採用數字錶法隨機分為對照組和觀察組,各60例.兩組患者均接受基礎治療,包括降糖、降壓、營養神經以及調節血脂等,觀察組在此基礎上加用莫沙必利與胰激肽原酶治療,兩組治療時間均為3週.觀察兩組療效、血糖、血脂、尿動力學、生活質量以及不良反應髮生率.結果 觀察組總有效率為93.33％,明顯高于對照組的65.00％(χ2=14.602,P＜0.0l)；觀察組不良反應髮生率為8.33％,明顯低于對照組的20.00％(χ2=11.368,P＜0.01).結論 莫沙必利聯閤胰激肽原酶治療糖尿病神經源性膀胱的療效顯著,能夠明顯改善患者的臨床癥狀及提高患者的生活質量,應在臨床上加以推廣併應用.
목적 탐토막사필리연합이격태원매치료당뇨병신경원성방광(DNB)적료효급안전성.방법 장120례당뇨병신경원성방광환자채용수자표법수궤분위대조조화관찰조,각60례.량조환자균접수기출치료,포괄강당、강압、영양신경이급조절혈지등,관찰조재차기출상가용막사필리여이격태원매치료,량조치료시간균위3주.관찰량조료효、혈당、혈지、뇨동역학、생활질량이급불량반응발생솔.결과 관찰조총유효솔위93.33％,명현고우대조조적65.00％(χ2=14.602,P＜0.0l)；관찰조불량반응발생솔위8.33％,명현저우대조조적20.00％(χ2=11.368,P＜0.01).결론 막사필리연합이격태원매치료당뇨병신경원성방광적료효현저,능구명현개선환자적림상증상급제고환자적생활질량,응재림상상가이추엄병응용.
Objective To explore the efficacy and safety of mosapride combined withpancreatic kallikrein in the treatment of diabetic neurogenic bladder(DNB).Methods According to the digital table,120 patients with DNB were randomly divided into the control group and the observation group,each group 60 cases,All patients received basic treatment,including reducing blood glucose,reducing blood pressure,nutrition nerve and regulating blood lipids,and the observation group was accepted the treatment of original enzyme plus mosapride pancreatic kinin on basis of the above treatment.The treatment time of the two groups was both 3 weeks,The effect,blood sugar,blood hpids,urodynamic,quality of life,and the incidence of adverse reactions were observed.Results The total effective rate of the observation group was 93.33％,which was significantly higher than that of the control group (65.00％) (χ2 =14.602,P ＜ 0.01) ；the adverse reaction rate of the observation group was 8,33％,which was significantly lower than that of the control group(20.00％)(χ2 =11.368,P ＜ 0.01),Conclusion Mosapride combined with pancreatic kallikrein in thetreatment of DNB has better effect,and could significantly improve the clinical symptoms and quality of life of patients.So it should be promoted and applied.
